Increased mortality in ankylosing spondylitis is related to disease activity
- PMID: 21784726
- DOI: 10.1136/ard.2011.151191
Increased mortality in ankylosing spondylitis is related to disease activity
Abstract
Background: The onset of disease in ankylosing spondylitis (AS) is generally earlier than in other joint diseases, exposing patients to a prolonged burden of disease. Whether this is associated with excess mortality is still uncertain. Radiation therapy for AS has previously been shown to increase mortality. The present study investigated standardised mortality ratios, causes of death and survival predictors in a large regional cohort of patients with AS.
Method: A total of 677 patients with AS followed at our hospital since 1977 were matched by gender, age and postal area to three controls from the general population and standardised mortality rates (SMRs) were calculated. Cause of death was established using patients' hospital records. In a subset of 360 patients, clinical and demographic data collected during an earlier research visit (1998-2000) were used in a prospective multivariate analysis of predictors for mortality in AS.
Results: The crude mortality among patients with AS in this study was 14.5% (98 patients); SMR was only significantly increased among male patients compared with female patients (1.63 vs 1.38, p<0.001). Circulatory disease was the most frequent cause of death (40.0%), followed by malignant (26.8%) and infectious (23.2%) diseases. Factors independently associated with reduced survival were diagnostic delay (OR 1.05), increasing levels of C-reactive protein (OR 2.68), work disability (OR 3.65) and not using any non-steroidal anti-inflammatory drugs (OR 4.35).
Conclusions: Mortality is increased in patients with AS and circulatory disease is the most frequent cause of death. Parameters reflecting the duration and intensity of inflammation are associated with reduced survival. These results indicate that, to improve long-term survival in AS, there is a need for early detection and anti-inflammatory treatment as well as a vigilant approach for cardiovascular risk factors.
Similar articles
-
Mortality among patients with ankylosing spondylitis not given X-ray therapy.N Engl J Med. 1977 Sep 15;297(11):572-6. doi: 10.1056/NEJM197709152971103. N Engl J Med. 1977. PMID: 887115
-
Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality: A Population-Based Study.Ann Intern Med. 2015 Sep 15;163(6):409-16. doi: 10.7326/M14-2470. Ann Intern Med. 2015. PMID: 26258401
-
Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.Trials. 2016 Jul 22;17(1):337. doi: 10.1186/s13063-016-1438-6. Trials. 2016. PMID: 27449221 Free PMC article. Clinical Trial.
-
Mortality in spondylarthritis.Joint Bone Spine. 2011 Oct;78(5):466-70. doi: 10.1016/j.jbspin.2011.02.012. Epub 2011 Mar 29. Joint Bone Spine. 2011. PMID: 21450507 Review.
-
[Ankylosing spondylitis is associated with increased cardiovascular morbidity and mortality].Ugeskr Laeger. 2011 May 23;173(21):1503-7. Ugeskr Laeger. 2011. PMID: 21627914 Review. Danish.
Cited by
-
Treatment strategies in axial spondyloarthritis: what, when and how?Rheumatology (Oxford). 2020 Oct 1;59(Suppl4):iv79-iv89. doi: 10.1093/rheumatology/keaa435. Rheumatology (Oxford). 2020. PMID: 33053192 Free PMC article. Review.
-
Biologic therapies for spondyloarthritis: what is new?Curr Rheumatol Rep. 2012 Oct;14(5):422-7. doi: 10.1007/s11926-012-0282-2. Curr Rheumatol Rep. 2012. PMID: 22855297 Review.
-
All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study.Rheumatology (Oxford). 2022 Nov 28;61(12):4656-4666. doi: 10.1093/rheumatology/keac210. Rheumatology (Oxford). 2022. PMID: 35377442 Free PMC article.
-
Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK.Pharmacoeconomics. 2018 Aug;36(8):1015-1027. doi: 10.1007/s40273-018-0675-9. Pharmacoeconomics. 2018. PMID: 29797186 Free PMC article.
-
The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis.Eur J Health Econ. 2020 Feb;21(1):45-54. doi: 10.1007/s10198-019-01110-w. Epub 2019 Sep 14. Eur J Health Econ. 2020. PMID: 31522361
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials